SLXNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SLXNW
Silexion Therapeutics Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.15+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $105.17K
- P/E (TTM)
- 0.0
- Dividend yield
- –
Ownership
Who owns Silexion Therapeutics's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 1 sales
Net sold $31.03K
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| CVI Investments, Inc. | 339,000 | 8.50% | 13G (passive) | Jan 15, 2025 |
| Mitchell P. Kopin | 325,000 | 9.40% | 13G (passive) amendment | Dec 31, 2025 |
| Daniel B. Asher | 244,771 | 9.99% | 13G (passive) | Sep 11, 2025 |
| Easton Jeff | 212,500 | 6.40% | 13G (passive) amendment | Sep 30, 2025 |
| Guangzhou Sino-Israel Bio-Industry Investment Fund (LLP) | 1,987,082 | 13.80% | 13D (active) | Aug 15, 2024 |
| Ilan Levin | 1,954,056 | 17.70% | 13D (active) amendment | Sep 18, 2026 |
| Moringa Partners Ltd | 1,391,827 | 10.60% | 13D (active) amendment | Jul 30, 2026 |
| Moringa Sponsor, LP | 1,382,346 | 32.99% | 13D (active) amendment | May 14, 2026 |
| Lincoln Alternative Strategies LLC | 131,250 | 6.18% | 13G (passive) | Sep 12, 2025 |
| Orca Capital AG | 131,250 | 6.20% | 13G (passive) | Sep 11, 2025 |
| The Goldman Sachs Group, Inc. | 112,242 | 6.60% | 13G (passive) | Dec 31, 2024 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Ilan Hadar | Chairman and CEO, Director | 16,547 | Jun 8, 2026 |
| Mitchell Shirvan | CSO and CDO | 8,789 | Jun 8, 2026 |
| Hadar Mirit Horenshtein | CFO and Secretary | 12,515 | Jun 8, 2026 |
| Shlomo Noy | Director | 25,399 | Feb 25, 2026 |
| Amnon Peled | Director | 8,237 | Feb 23, 2026 |
| Ruth Alon | Director | 10,228 | Feb 23, 2026 |
| Avner Lushi | Director | 25,399 | Feb 23, 2026 |
| Dror Yosef Abramov | Director | 10,180 | Feb 23, 2026 |
| Ilan Levin | Director, 10% owner | – | Jan 27, 2026 |
| Moringa Sponsor, LP | 10% owner | 458,452 | Jan 27, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mitchell Shirvan CSO and CDO | Jun 4, 2026 | Award | +6,000 | – | – | 8,789 |
| Hadar Mirit Horenshtein CFO and Secretary | Jun 4, 2026 | Award | +7,500 | – | – | 12,515 |
| Ilan Hadar Chairman and CEO, Director | Jun 4, 2026 | Award | +10,000 | – | – | 16,547 |
| Mitchell Shirvan CSO and CDO | Mar 26, 2026 | Sale | −22,818 | $1.36 | $31.03K | 27,889 |
| Shlomo Noy Director | Feb 20, 2026 | Award | +9,091 | – | – | 25,399 |
| Ruth Alon Director | Feb 20, 2026 | Award | +9,091 | – | – | 10,228 |
| Hadar Mirit Horenshtein CFO and Secretary | Feb 20, 2026 | Award | +49,726 | – | – | 50,146 |
| Avner Lushi Director | Feb 20, 2026 | Award | +9,091 | – | – | 25,399 |
| Dror Yosef Abramov Director | Feb 20, 2026 | Award | +9,091 | – | – | 10,180 |
| Ilan Hadar Chairman and CEO, Director | Feb 20, 2026 | Award | +64,350 | – | – | 65,471 |
| Amnon Peled Director | Feb 20, 2026 | Award | +7,576 | – | – | 8,237 |
| Mitchell Shirvan CSO and CDO | Feb 20, 2026 | Award | +49,726 | – | – | 50,707 |
| Moringa Sponsor, LP 10% owner | Sep 15, 2025 | Award | +450,000 | $4.00 | $1.80M | 456,970 |
| Moringa Sponsor, LP 10% owner | Aug 7, 2025 | Other | −5,550 | – | – | 6,970 |
| Dror Yosef Abramov Director | Feb 9, 2025 | Award | +794 | – | – | 794 |
| Avner Lushi Director | Feb 9, 2025 | Award | +1,587 | – | – | 1,587 |
| Amnon Peled Director | Feb 9, 2025 | Award | +661 | – | – | 661 |
| Ruth Alon Director | Feb 9, 2025 | Award | +794 | – | – | 794 |
| Shlomo Noy Director | Feb 9, 2025 | Award | +1,587 | – | – | 1,587 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.